ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Osteoarthritis"

  • Abstract Number: 1122 • ACR Convergence 2021

    Patient-perceived Solutions to the Treatment Barriers in Knee Osteoarthritis: A Qualitative Study from a Diverse Patient Group Including Racial/ethnic Minorities

    Jasvinder Singh, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Knee osteoarthritis (OA) has worse outcomes in racial/ethnic minorities. Yet, most of the qualitative studies include primarily Caucasian people with knee OA, with minimal…
  • Abstract Number: 1456 • ACR Convergence 2021

    Cannabidiol Treatment in Hand Osteoarthritis and Psoriatic Arthritis – A Randomized, Double-blind Placebo-controlled Trial

    Jonathan Vela1, Salome Kristensen2, Lene Dreyer2, Kristian Kjær Petersen3 and Lars Arendt Nielsen3, 1Dept. of Rheumatology Aalborg Denmark, Aalborg, Denmark, 2Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, 3Aalborg University, Aalborg, Denmark

    Background/Purpose: Medical cannabis is increasing in popularity yet the recent International Association for the Study of Pain presidential task force on cannabis and cannabinoid analgesia…
  • Abstract Number: 1904 • ACR Convergence 2021

    “Why Does My Knee Hurt After I Got My Knee Replaced?”: Evaluation of Neuropathic-like Symptoms and Objective Signs of Neuropathy Post-Knee Replacement in Patients with Knee Osteoarthritis

    Devin Driscoll1, Priyanka Ballal1, Na Wang2, Laura Frey-Law3, Cora Lewis4, Michael Nevitt5 and Tuhina Neogi1, 1Boston University School of Medicine, Boston, MA, 2Boston University, Boston, MA, 3University of Iowa, Iowa City, IA, 4University of Alabama Birmingham, Birmingham, AL, 5University of California San Francisco, Orinda, CA

    Background/Purpose: Some people with knee osteoarthritis (OA) have persistent pain post-knee replacement, but why this occurs is not fully understood. One possibility is post-surgical neuropathy.…
  • Abstract Number: 0011 • ACR Convergence 2021

    Differential Inflammation-mediated Function of Prokineticin 2 in the Synovial Fibroblasts of Patients with Rheumatoid Arthritis Compared to Osteoarthritis

    Kentaro Noda, Bianca Dufner and Rainer Straub, Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine I, University Hospital Regensburg, Regensburg, Germany

    Background/Purpose: Prokineticin 2 (PK2) is a secreted protein involved in several pathological and physiological processes, including the regulation of inflammation, sickness behaviors, and the circadian…
  • Abstract Number: 0223 • ACR Convergence 2021

    The Association of Clinical and Structural Knee Osteoarthritis with Physical Activity in the Middle-aged Population: The Netherlands Epidemiology of Obesity Study

    Sietse Terpstra1, Jeroen van der Velde1, Renée de Mutsert1, Dieuwke Schiphof2, Monique Reijnierse1, Frits Rosendaal1, Lotte van de Stadt1, Margreet Kloppenburg1 and Marieke Loef1, 1Leiden University Medical Center, Leiden, Netherlands, 2Erasmus Medical Center, Rotterdam, Netherlands

    Background/Purpose: Physical activity is a potential target for interventions in knee OA. However, most of the available studies concerning physical activity in individuals with knee…
  • Abstract Number: 0726 • ACR Convergence 2021

    Joint Safety of Tanezumab versus NSAIDs; A Combined Assessment of Benefit and Harm

    Robert Fountaine1, Robert Dworkin2, Anne Hickman1, Glenn Pixton3, Ed Whalen4, Christine West1 and Kenneth Verburg1, 1Pfizer Inc., Groton, CT, 2University of Rochester, Rochester, NY, 3Pfizer Inc., Morrisville, NC, 4Pfizer Inc., New York, NY

    Background/Purpose: Tanezumab, a monoclonal antibody against nerve growth factor, is in development for the relief of signs and symptoms of moderate to severe osteoarthritis (OA)…
  • Abstract Number: 0943 • ACR Convergence 2021

    Metabolomic Profiling of Synovial Tissue of Patients with Osteoarthritis

    Jessica Murillo Saich1, Roxana Coras2, Robert Meyer3 and Monica Guma4, 1University of California San Diego, La Jolla, CA, 2University of California San Diego/Department of Medicine, Autonomous University of Barcelona, San Diego, CA, 3San Diego VA Healthcare Service, La Jolla, CA, 4University of California San Diego/San Diego VA Healthcare Service/Department of Medicine, Autonomous University of Barcelona, La Jolla, CA

    Background/Purpose: Increasing evidence indicates that osteoarthritis (OA) progression is mediated not simply by progressive degeneration of cartilage, but also by low-grade synovial inflammation (synovitis) that…
  • Abstract Number: 1123 • ACR Convergence 2021

    “It’s a Dance Between Managing Both [Diabetes and Osteoarthritis]”: A Qualitative Study Exploring Perspectives of Persons with Knee Osteoarthritis and Type 2 Diabetes Mellitus on the Impact of Osteoarthritis on Diabetes Management and Daily Life

    Lauren King1, Esther Waugh1, Crystal McKay1, Ian Stanaitis2 and Gillian Hawker1, 1University of Toronto, Toronto, ON, Canada, 2Women's College Hospital, Toronto, ON, Canada

    Background/Purpose: The links between osteoarthritis (OA) and other common chronic conditions, such as type 2 diabetes mellitus (T2DM), are increasingly being appreciated in epidemiological studies.…
  • Abstract Number: 1468 • ACR Convergence 2021

    Intra-articular (IA) Injection of Empty Large Multilamellar Vesicles Liposomes Reduces Cartilage Degeneration in Rat Osteoarthritis Model

    Alison Bendele1, Jacob Favret1, Gadi Sarfati2, Ronny Pinkus2 and Roni Wechsler2, 1Bolder BioPATH Inc., Boulder, CO, 2Moebius Medical LTD, Tel Aviv, Israel

    Background/Purpose: A suspension of empty large multilamellar vesicles (MLV) liposomes composed of dimyristoylphosphatidylcholine (DMPC) and dipalmitoylphosphatidylcholine (DPPC), is currently under clinical development for symptomatic knee…
  • Abstract Number: 0026 • ACR Convergence 2021

    Synovial Fibroblasts Acquire a Proinflammatory and Destructive Phenotype After Exposure to αS1-Casein (CSN1S1)

    Nadine Honke1, Tim Appel1, Matthias Schneider2 and Georg Pongratz3, 1Department of Rheumatology, Hiller Research Center Rheumatology, University Hospital Düsseldorf, Germany (* contributed equally), Düsseldorf, Germany, 2Policlinic & Hiller Research Unit Rheumatology, UKD, Heinrich-Heine University, Düsseldorf, Germany, 3Polyclinic and Functional Area for Rheumatology & Hiller Research Center Rheumatology, University Hospital Düsseldorf, Düsseldorf, Germany

    Background/Purpose: The milk protein αS1-Casein (CSN1S1) was described to be overexpressed in synovial tissue of patients with rheumatoid arthritis (RA) and osteoarthritis (OA). Recently we…
  • Abstract Number: 0224 • ACR Convergence 2021

    Effects of Kinesiophobia and Physical Function on Physical Activity in Adults with Knee Osteoarthritis

    Burcu Aydemir and Kharma Foucher, University of Illinois at Chicago, Chicago, IL

    Background/Purpose: Only a small proportion of people with knee osteoarthritis (OA) meet the recommended guidelines for physical activity and it is still unclear why. Lacking…
  • Abstract Number: 0727 • ACR Convergence 2021

    Total Joint Replacements in Three Phase 3 Studies of Tanezumab in Patients with Osteoarthritis

    John Carrino1, Timothy McAlindon2, Eric Vignon3, Mark Brown4, Aimee Burr4, Robert Fountaine4, Glenn Pixton5, Lars Viktrup6, Christine West4 and Kenneth Verburg4, 1Hospital for Special Surgery, New York, NY, 2Tufts Medical Center, Arlington, MA, 3Université Claude Bernard Lyon 1, Lyon, France, 4Pfizer Inc., Groton, CT, 5Pfizer Inc., Morrisville, NC, 6Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: Tanezumab (TNZ) is an antibody against nerve growth factor that has demonstrated efficacy in the management of osteoarthritis (OA). Due to the potential risk…
  • Abstract Number: 1028 • ACR Convergence 2021

    Knee Osteoarthritis and Mortality: The Osteoarthritic Initiative

    Jane Cauley1, Michael Nevitt2, Kai Sun3, Jason Maeda3, C. Kent Kwoh4, Leena Sharma5, Rebecca Jackson6, Susan Rubin3 and Marc Hochberg7, 1University of Pittsburgh Graduate School of Public Health, Pittsbugh, PA, 2University of California San Francisco, Orinda, CA, 3University of California San Francisco, San Francisco, CA, 4University of Arizona College of Medicine, Tuscon, AZ, 5Northwestern University, Chicago, IL, 6Ohio State University, Columbus, OH, 7University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: A recent international individual participant data (IPD) meta-analysis (n=10,723) reported a 35-37% increased mortality risk among individuals with painful knees (no radiographic OA) and…
  • Abstract Number: 1124 • ACR Convergence 2021

    Examining the Relationships Between Treatment and Pain and Physical Function Outcomes in Patients with Osteoarthritis: A Mediation Modeling Approach

    Lucy Abraham1, Robert Dworkin2, Dennis C. Turk3, John D. Markman2, David A. Williams4, Andrew G Bushmakin5, Jerry A. Hall6, David C. Semel7, Joseph C Cappelleri5 and Ruoyong Yang8, 1Pfizer Ltd., Tadworth, United Kingdom, 2University of Rochester, Rochester, NY, 3University of Washington, Seattle, WA, 4University of Michigan, Ann Arbor, MI, 5Pfizer Inc, Groton, CT, 6Eli Lilly and Company, Indianapolis, IN, 7Pfizer, New York, NY, 8Pfizer Inc., New York, NY

    Background/Purpose: To better understand the complex relationships between treatment and pain and physical function (PF) outcomes, we investigated a set of mediation models of osteoarthritis…
  • Abstract Number: 1470 • ACR Convergence 2021

    Cartilage Epigenetic Changes Induced by Microbial DNA Amplified from Human OA Samples

    Vladislav Izda1, Christopher Dunn2, Cassandra Sturdy1, Jake Martin1, Cassandra Velasco2, Paul Jacob3 and Matlock Jeffries1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Oklahoma Joint Reconstruction Institute, Oklahoma City, OK

    Background/Purpose: Strong links between epigenetic changes, particularly alterations in DNA methylation, have been linked with the onset and progression of knee osteoarthritis (OA); however, the…
  • « Previous Page
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • …
  • 63
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology